Results from long awaited Ivermectin for COVID... - CLL Support
Results from long awaited Ivermectin for COVID-19 Oxford University (PRINCIPLE) study of 8,800 COVID positive participants. It doesn't help!
You need to be a member of this community to see this post.
Read more about...
22 Replies
You need to be a member of this community to see hidden responses.
Not what you're looking for?
You may also like...
Clinical Trials of Monoclonal antibodies AZD7442 against SARS=CoV-2 (COVID19) - majority of sites in UK and USA
There are two clinical trials of monoclonal antibodies that target covid19.
AstraZeneca is...
Research shows blood cancer patients generate strong T cell immunity after SARS-CoV-2 vaccination
Today, the Doherty Institute in Melbourne, Australia, released a statement about a research study...
Development of AstraZeneca's SARS-CoV2 spike monoclonal antibodies (AZD7442)
Thank you bennevisplace for posting about AstraZeneca's monoclonal antibody clinical trial for...
Important SARS-CoV-2 and Covid-19 information for Chronic Lymphocytic Leukaemia/CLL patients
This post, prepared in collaboration with @[52122] , draws together some earlier posts...
STORM CHASER MISSES THE TARGET
Following hard on the heels of Regeneron, who just posted lukewarm results from the RECOVERY trial...
Related Posts
An unusual, potent antibody to SARS-CoV-2 variants is isolated from a recovered patient
Vaccine candidate was found to be more than 90% effective in preventing COVID-19 in participants without evidence of prior SARS-CoV-2 infect- AstraZeneca Covid-19 vaccine study put on hold due to suspected adverse reaction in participant in the U.K.
Longitudinal analysis shows durable and broad immune memory after SARS-CoV-2 infection with persisting antibody responses and memory B and T
COVID-19 among fit patients with CLL treated with venetoclax-based combinations
